{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:08:44Z","timestamp":1791943724102,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer immunotherapy represents a major breakthrough in oncology, particularly with immune checkpoint inhibitors (ICIs) and CAR-T cell therapies. Despite improved outcomes, challenges such as immune-related adverse events (irAEs) and treatment resistance limit clinical use. Artificial intelligence (AI) offers new opportunities to address these barriers, including target identification, efficacy prediction, toxicity monitoring, and personalized treatment design. This review highlights recent advances in AI applications for biomarker discovery, safety evaluation, gene editing, nanotechnology, and microbiome modulation, integrating evidence from clinical and preclinical studies. We also discuss future directions and challenges in applying AI to cancer immunotherapy, aiming to support further research and clinical translation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1676112","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:22:47Z","timestamp":1761891767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Applications of artificial intelligence in cancer immunotherapy: a frontier review on enhancing treatment efficacy and safety"],"prefix":"10.3389","volume":"16","author":[{"given":"Ji\u2019an","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.3390\/cancers15245857","article-title":"Navigating the immune maze: pioneering strategies for unshackling cancer immunotherapy resistance","volume":"15","author":"Yao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8052212","DOI":"10.1155\/2022\/8052212","article-title":"Recent advances and next breakthrough in immunotherapy for cancer treatment","author":"Yang","year":"2022","journal-title":"J Immunol Res 2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1039\/D2TB00048B","article-title":"Supramolecular biomaterials for enhanced cancer immunotherapy","volume":"10","author":"Zhang","year":"2022","journal-title":"J Mater Chem B"},{"key":"B6","article-title":"The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response","volume":"15","author":"Wang","year":"2023","journal-title":"Am J Transl Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","article-title":"Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine","volume":"16","author":"Serrano","year":"2024","journal-title":"Pharmaceutics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108591","DOI":"10.1016\/j.pharmthera.2024.108591","article-title":"Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective","volume":"254","author":"Yang","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases13010024","article-title":"Integrating AI into cancer immunotherapy-A narrative review of current applications and future directions","volume":"13","author":"Olawade","year":"2025","journal-title":"Diseases"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.5c00489","article-title":"Nanotechnology-enhanced siRNA delivery: revolutionizing cancer therapy","volume":"8","author":"Esmaeilpour","year":"2025","journal-title":"ACS Appl Bio Mater"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/jcm12041279","article-title":"Artificial intelligence-assisted transcriptomic analysis to advance cancer immunotherapy","volume":"12","author":"Gui","year":"2023","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-023-01456-y","article-title":"The artificial intelligence and machine learning in lung cancer immunotherapy","volume":"16","author":"Gao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1394003","article-title":"Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy","volume":"15","author":"Bulashevska","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008817","article-title":"Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma","volume":"12","author":"M\u00f8rk","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/diagnostics15030397","article-title":"Optimizing cancer treatment: exploring the role of AI in radioimmunotherapy","volume":"15","author":"Azadinejad","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19333","DOI":"10.1038\/s41598-025-01680-1","article-title":"Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer","volume":"15","author":"Vasudevan","year":"2025","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction","volume":"91","author":"Li","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2553","article-title":"Leveraging artificial intelligence for neoantigen prediction","volume":"85","author":"Zeng","year":"2025","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1530507","article-title":"Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy","volume":"14","author":"Qiao","year":"2024","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","article-title":"Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000557","article-title":"Integrative multi-omics analysis reveals molecular subtypes of ovarian cancer and constructs prognostic models","volume":"48","author":"Zhou","year":"2025","journal-title":"J Immunother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10732748241305237","DOI":"10.1177\/10732748241305237","article-title":"Nomogram for predicting survival post-immune therapy in cholangiocarcinoma based on inflammatory biomarkers","volume":"31","author":"Jin","year":"2024","journal-title":"Cancer Control"},{"key":"B23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.12688\/wellcomeopenres.23021.1","article-title":"The ubuntu way: ensuring ethical AI integration in health research","volume":"9","author":"Odero","year":"2024","journal-title":"Wellcome Open Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt2641","article-title":"Digital channel-enabled distributed force decoding via small datasets for hand-centric interactions","volume":"11","author":"Tang","year":"2025","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e57754","DOI":"10.2196\/57754","article-title":"Data ownership in the AI-powered integrative health care landscape","volume":"12","author":"Liu","year":"2024","journal-title":"JMIR Med Inform"},{"key":"B26","doi-asserted-by":"publisher","first-page":"217265","DOI":"10.1016\/j.canlet.2024.217265","article-title":"Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma","volume":"605","author":"Alhalabi","year":"2024","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10916-021-01790-z","article-title":"Trustworthy augmented intelligence in health care","volume":"46","author":"Crigger","year":"2022","journal-title":"J Med Syst"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15433","DOI":"10.1038\/s41598-024-65845-0","article-title":"Uncovering hidden and complex relations of pandemic dynamics using an AI driven system","volume":"14","author":"Demirbaga","year":"2024","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"102497","DOI":"10.1016\/j.arr.2024.102497","article-title":"AI-driven innovations in Alzheimer\u2019s disease: Integrating early diagnosis, personalized treatment, and prognostic modelling","volume":"101","author":"Kale","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"Of2","DOI":"10.1158\/2159-8290.CD-RW2023-002","article-title":"IL7 genetic variation predicts immune-related adverse events","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.10.24308518","article-title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","volume":"13","author":"Middha","year":"2024","journal-title":"medRxiv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12911-021-01564-0","article-title":"Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies","volume":"21","author":"Iivanainen","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2398309","DOI":"10.1080\/21645515.2024.2398309","article-title":"Predictive value of near-term prediction models for severe immune-related adverse events in Malignant tumor PD-1 inhibitor therapy","volume":"20","author":"Du","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12967-023-04172-w","article-title":"Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens","volume":"21","author":"Shen","year":"2023","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2332175","DOI":"10.1080\/1547691X.2024.2332175","article-title":"Fine tuning of the innate and adaptive immune responses by Interleukin-2","volume":"21","author":"Sakellariou","year":"2024","journal-title":"J Immunotoxicol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"106628","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.11.008","article-title":"Artificial intelligence for prediction of response to cancer immunotherapy","volume":"87","author":"Yang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40001-023-01625-2","article-title":"Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence","volume":"29","author":"Zakariya","year":"2024","journal-title":"Eur J Med Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-1270","article-title":"Artificial intelligence can predict personalized immunotherapy outcomes in cancer","volume":"13","author":"Huang","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10732748241274978","DOI":"10.1177\/10732748241274978","article-title":"Cutaneous oncology: strategies for melanoma prevention, diagnosis, and therapy","volume":"31","author":"Saeed","year":"2024","journal-title":"Cancer Control"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0099","article-title":"MANIFEST: multiomic platform for cancer immunotherapy","volume":"15","author":"Lim","year":"2025","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41698-024-00770-z","article-title":"A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types","volume":"8","author":"Brattoli","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/biom15040589","article-title":"Optimizing immunotherapy: the synergy of immune checkpoint inhibitors with artificial intelligence in melanoma treatment","volume":"15","author":"Saleem","year":"2025","journal-title":"Biomolecules"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20892\/j.issn.2095-3941.2024.0376","article-title":"Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization","volume":"22","author":"Chang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-4690-8_16","article-title":"Artificial intelligence-based genome editing in CRISPR\/cas9","volume":"2952","author":"Pandey","year":"2025","journal-title":"Methods Mol Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"109137","DOI":"10.1016\/j.compbiomed.2024.109137","article-title":"The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy","volume":"182","author":"Boretti","year":"2024","journal-title":"Comput Biol Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12032-025-02783-5","article-title":"Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices","volume":"42","author":"Kamli","year":"2025","journal-title":"Med Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12967-024-06013-w","article-title":"Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR","volume":"23","author":"Abbasi","year":"2025","journal-title":"J Transl Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.3390\/s23249676","article-title":"Smart sensor control and monitoring of an automated cell expansion process","volume":"23","author":"Nettleton","year":"2023","journal-title":"Sensors (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1009883","DOI":"10.1371\/journal.pcbi.1009883","article-title":"In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes","volume":"18","author":"Naghizadeh","year":"2022","journal-title":"PloS Comput Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1002\/cnr2.2045","article-title":"Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments","volume":"7","author":"Jayawickrama","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-022-01122-3","article-title":"Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy","volume":"17","author":"Zhang","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-025-01026-w","article-title":"Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention","volume":"22","author":"Gao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332125","article-title":"Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events","volume":"74","author":"De Martin","year":"2025","journal-title":"Gut"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e43262","DOI":"10.7759\/cureus.43262","article-title":"Unraveling the ethical enigma: artificial intelligence in healthcare","volume":"15","author":"Jeyaraman","year":"2023","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12911-020-01332-6","article-title":"Explainability for artificial intelligence in healthcare: a multidisciplinary perspective","volume":"20","author":"Amann","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.cell.2023.03.035","article-title":"Massively parallel base editing to map variant effects in human hematopoiesis","volume":"186","author":"Martin-Rufino","year":"2023","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676112\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:22:51Z","timestamp":1761891771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676112\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1676112"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1676112","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1676112"}}